Press release
Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England
- Eligible transfusion-dependent beta thalassemia (TDT) patients in England will be able to access the therapy from today - - CASGEVY is one of the first
About this update from Vertex Pharmaceuticals Incorporated
[{"type":"text","content":"\n- Eligible transfusion-dependent beta thalassemia (TDT) patients in England will be able to access the therapy from today -\n\n\n- CASGEVY is one of the first medicines funded by NHS England’s Innovative Medicines Fund -\n\n\n LONDON--(BUSINESS WIRE)--\nVertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY™ (exagamglogene autotemcel), from today.\n\n\nThe reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY’s use in the NHS.\n\n\nThe United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) granted CASGEVY the first authorization in the world for a CRISPR-based gene-editing therapy on November 15, 2023.\n\n\n“Securing access to CASGEVY is a historic moment for people living with transfusion-dependent beta thalassemia who, for too long, have had limited options for this life-shortening disease,” said Ludovic Fenaux, Senior Vice President, Vertex International. “Through collaboration with NHS England and NICE, we have reached this landmark agreement that recognizes the value a one-time treatment can provide to patients, their families and the health care system.”\n\n\nThe administration of the therapy requires experience in stem cell transplantation and the management of hemoglobinopathies; therefore, Vertex is engaging with experienced hospitals throughout England to establish a network of independently operated authorized treatment centers (ATCs).\n\n\nVertex continues to work collaboratively with NICE and NHS England to ensure eligible sickle cell disease (SCD) patients in England can also access this treatment as soon as possible. In the European Union, Vertex is working closely with reimbursement authorities to bring this innovative therapy to eligible SCD and TDT patients rapidly as the company has done in the United States, the Kingdom of Saudi Arabia and Bahrain.\n\n\nAbout Transfusion-Dependent Beta Thalassemia (TDT)\n\n\nTDT is a serious, life-threatening genetic disease. TDT patients report health-related quality of life scores below the general population and significant health care resource utilization. TDT requires frequent blood transfusions an...